Roche Lung-Cancer Drug Candidate Beats Existing Therapies in Late-Stage Trial
6 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"Roche Lung-Cancer Drug Candidate Beats Existing Therapies in Late-Stage Trial" is generating significant coverage in the Business category, with 6 articles from 6 distinct sources tracked by PULSE so far.
Outlets currently covering the story include Bloomberg.com, Endpoints News, Fierce Biotech and STAT. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 47d ago.
Quick answers
Why is "Roche Lung-Cancer Drug Candidate Beats Existing Therapies in Late-Stage Trial" trending?
Because 6 independent news sources published 6 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (6)
- Roche’s Lung Cancer Pill Outperforms Rival Drugs in Late Trial Bloomberg.com · 49d ago
- Roche’s KRAS G12C inhibitor beats rivals in head-to-head Phase 3 study Endpoints News · 49d ago
- Roche orchestrates phase 3 KRAS lung cancer win over Amgen, BMS Fierce Biotech · 49d ago
- Roche drug sets new standard for KRAS-driven lung cancer STAT · 49d ago
- Roche's divarasib bests KRAS G12C rivals in late-stage NSCLC study FirstWord PHARMA · 49d ago
- Roche Lung-Cancer Drug Candidate Beats Existing Therapies in Late-Stage Trial WSJ · 49d ago
Topics
Related trends
‘The Odyssey’ Beats ‘Deadpool & Wolverine’ as Biggest R-Rated Movie of All Time With $1.35 Billion
1 news sources are covering this Entertainment story right now — PULSE is tracking how fast it spreads.
Drug Enforcement Administration joins probe into Hayden Panettiere's death: Sources
2 news sources are covering this Entertainment story right now — PULSE is tracking how fast it spreads.
EyePoint Stock Craters 69% After Drug Trial Failure. It May Be an Overreaction.
2 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Lung cancer can stay silent for years: Who should get screened and why early detection matters
Medical experts and news outlets are highlighting the critical need for early lung cancer screening to combat the disease's tendency to remain silent for years.
AstraZeneca Ends Phase 3 Lung Cancer Drug Trial After Review
AstraZeneca ends a Phase 3 lung cancer drug trial for volrustomig after a formal review determines success is unlikely.
Drug Taken for Common Condition May Be Slowing Alzheimer’s Decline
8 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.